OTE0004 5 WB 0622 OTB0007 WA 06.Mär 09
euro adhoc / Board of Directors (Appointments and Changes)

euro adhoc: Intercell AG / Board of Directors (Appointments and Changes) / Intercell names Reinhard Kandera Chief Financial Officer (E)

Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.

06.03.2009

Vienna, Austria, March 6, 2009 - Intercell AG (VSE: ICLL) today announced that Reinhard Kandera has been appointed as Chief Financial Officer (CFO). In his new role he will be responsible for the global Finance Function and Investor Relations of Intercell AG.

Reinhard Kandera is currently CFO of Intercell´s US subsidiary (formerly Iomai Corporation), which was acquired in 2008. He joined Intercell in 2001 and has held various positions within Finance including Global Head of Investor Relations and Head of Finance and Controlling. Reinhard Kandera has made pivotal contributions to the successful integration of Intercell´s acquisitions in Scotland and in the USA and has implemented all the strategic funding activities of the company. Before joining Intercell he worked for Deutsche Bank AG. He holds doctorate degrees in both law and finance.

The prior CFO, Werner Lanthaler, will be leaving the company with effect from March 6 to join Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) as Chief Executive Officer (CEO). Werner Lanthaler has completed a full hand-over of his responsibilities to Reinhard Kandera as would be expected given the long, successful working relationship between both executives and most friendly nature of the transition.

Werner Lanthaler contributed significantly to the success of Intercell for more than 8 years cumulating in the approval of Intercell´s first marketed product. Werner Lanthaler has spearheaded a series of excellent strategic partnerships, as well as achieved sustainable profitability and a very solid financial situation without further funding needs for Intercell. He also made key contributions to private venture fund raisings in the early years of the company, the IPO in 2005, the strategic alliance with Novartis in 2007 and several transforming strategic initiatives including two major acquisitions.

"Werner Lanthaler´s contributions were pivotal to making Intercell one of the most successful young biotech companies globally and we want to thank him for his outstanding work. We are glad that he will continue to be available as a strategic advisor to the company and wish him all the best for his future plans", stated Michel Gréco, Chairman of the Intercell Supervisory Board

"It has been a great experience for me and the Management Board and all employees of Intercell to build the company together with Werner. We understand and respect his decision and we would like to express our deep gratitude for his outstanding performance. We are very happy that Reinhard Kandera will now take over the role of the CFO. His experience and knowledge of all company processes make him highly qualified for the next growth phase of Intercell", stated Gerd Zettlmeissl, Chief Executive Officer of Intercell.

"It has always been a privilege to contribute towards making Intercell an outstanding player in the global vaccine industry, and I am convinced that the company is excellently positioned for its next successful growth steps. I want to thank my colleagues and especially our investors and business partners for their strong support over the past 8 years, which made my time at Intercell a fantastic personal and professional experience", stated Werner Lanthaler.

The Management Board of Intercell AG will consist of Gerd Zettlmeissl (Chief Executive Officer), Thomas Lingelbach (Chief Operating Officer) and Alexander von Gabain (Chief Scientific Officer) until further appointments will be made.

Further inquiry note:
Intercell AG
Lucia Malfent
Head of Corporate Communications
P.: +43 1 20620-1303
lmalfent@intercell.com

end of announcement euro adhoc

emitter: Intercell AG
Campus Vienna Biocenter 3
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: investors@intercell.com
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime, ATX
stockmarkets: official market: Wiener Börse AG
language: English

***OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT***

OTE0004 2009-03-06/08:08